
## Simon Zhornitsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8150505/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cerebral Volumetric Correlates of Apathy in Alzheimer's Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort. Journal of Alzheimer's Disease, 2022, 85, 1251-1265.	2.6	9
2	Emotion Processing Dysfunction in Alzheimer's Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology. American Journal of Alzheimer's Disease and Other Dementias, 2022, 37, 153331752210828.	1.9	12
3	Gray matter volumetric correlates of dimensional impulsivity traits in children: Sex differences and heritability. Human Brain Mapping, 2022, 43, 2634-2652.	3.6	11
4	The effects of androgen deprivation on working memory and quality of life in prostate cancer patients: The roles of hypothalamic connectivity. Cancer Medicine, 2022, 11, 3425-3436.	2.8	9
5	Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 118, 110575.	4.8	11
6	Acute effects of partial CB1 receptor agonists on cognition – A meta-analysis of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110063.	4.8	19
7	The Neural Processes Interlinking Social Isolation, Social Support, and Problem Alcohol Use. International Journal of Neuropsychopharmacology, 2021, 24, 333-343.	2.1	12
8	Problem drinking alters gray matter volume and food cue responses of the lateral orbitofrontal cortex. Addiction Biology, 2021, 26, e12857.	2.6	6
9	Sex differences in neural responses to reward and the influences of individual reward and punishment sensitivity. BMC Neuroscience, 2021, 22, 12.	1.9	21
10	Reward-Related Responses and Tonic Craving in Cocaine Addiction: An Imaging Study of the Monetary Incentive Delay Task. International Journal of Neuropsychopharmacology, 2021, 24, 634-644.	2.1	6
11	Perceived friendship and binge drinking in young adults: A study of the Human Connectome Project data. Drug and Alcohol Dependence, 2021, 224, 108731.	3.2	11
12	Distinct patterns of prefrontal cortical disengagement during inhibitory control in addiction: A meta-analysis based on population characteristics. Neuroscience and Biobehavioral Reviews, 2021, 127, 255-269.	6.1	20
13	Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis. Psychiatry Research - Neuroimaging, 2021, 317, 111380.	1.8	8
14	Noradrenergic correlates of chronic cocaine craving: neuromelanin and functional brain imaging. Neuropsychopharmacology, 2021, 46, 851-859.	5.4	10
15	Depression Mediates the Relationship between Childhood Trauma and Internet Addiction in Female but Not Male Chinese Adolescents and Young Adults. Journal of Clinical Medicine, 2021, 10, 5015.	2.4	11
16	Perceived stress, self-efficacy, and the cerebral morphometric markers in binge-drinking young adults. NeuroImage: Clinical, 2021, 32, 102866.	2.7	5
17	Hypothalamic response to cocaine cues and cocaine addiction severity. Addiction Biology, 2020, 25, e12682.	2.6	15
18	The effects of age on cerebral responses to self-initiated actions during social interactions: An exploratory study. Behavioural Brain Research, 2020, 378, 112301.	2.2	5

SIMON ZHORNITSKY

#	Article	IF	CITATIONS
19	Interdependent Neural Correlates of Reward and Punishment Sensitivity During Rewarded Action and Inhibition of Action. Cerebral Cortex, 2020, 30, 1662-1676.	2.9	13
20	Neural correlates of reward-directed action and inhibition of action. Cortex, 2020, 123, 42-56.	2.4	13
21	Heart Rate Variability, Cue-Evoked Ventromedial Prefrontal Cortical Response, and Problem Alcohol Use in Adult Drinkers. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 619-628.	1.5	13
22	The effects of age on reward magnitude processing in the monetary incentive delay task. NeuroImage, 2020, 207, 116368.	4.2	49
23	The interrelationship of body mass index with gray matter volume and resting-state functional connectivity of the hypothalamus. International Journal of Obesity, 2020, 44, 1097-1107.	3.4	32
24	Sex Differences in Neural Responses to the Perception of Social Interactions. Frontiers in Human Neuroscience, 2020, 14, 565132.	2.0	23
25	Gray matter volumetric correlates of behavioral activation and inhibition system traits in children: An exploratory voxel-based morphometry study of the ABCD project data. NeuroImage, 2020, 220, 117085.	4.2	35
26	Cue-elicited functional connectivity of the periaqueductal gray and tonic cocaine craving. Drug and Alcohol Dependence, 2020, 216, 108240.	3.2	10
27	Perceived burdensomeness and neural responses to ostracism in the Cyberball task. Journal of Psychiatric Research, 2020, 130, 1-8.	3.1	5
28	Resting state hypothalamic and dorsomedial prefrontal cortical connectivity of the periaqueductal gray in cocaine addiction. Addiction Biology, 2020, 26, e12989.	2.6	8
29	Pain and reward circuits antagonistically modulate alcohol expectancy to regulate drinking. Translational Psychiatry, 2020, 10, 220.	4.8	19
30	Interpersonal Risk Factors for Suicide in Cocaine Dependence: Association with Selfâ€Esteem, Personality Traits, and Childhood Abuse. Suicide and Life-Threatening Behavior, 2020, 50, 867-883.	1.9	13
31	Cultural differences in anterior cingulate cortical response to prediction error. Culture and Brain, 2019, 7, 67-79.	0.5	1
32	Reward sensitivity and electrodermal responses to actions and outcomes in a go/no-go task. PLoS ONE, 2019, 14, e0219147.	2.5	22
33	Hypothalamic Responses to Cocaine and Food Cues in Individuals with Cocaine Dependence. International Journal of Neuropsychopharmacology, 2019, 22, 754-764.	2.1	23
34	Posterior Cingulate Cortical Response to Active Avoidance Mediates the Relationship between Punishment Sensitivity and Problem Drinking. Journal of Neuroscience, 2019, 39, 6354-6364.	3.6	19
35	Social anxiety, posterior insula activation, and autonomic response during self-initiated action in a Cyberball game. Journal of Affective Disorders, 2019, 255, 158-167.	4.1	15
36	Cue-elicited craving, thalamic activity, and physiological arousal in adult non-dependent drinkers. Journal of Psychiatric Research, 2019, 116, 74-82.	3.1	22

SIMON ZHORNITSKY

#	Article	IF	CITATIONS
37	Alcohol Expectancy and Cerebral Responses toÂCue-Elicited Craving in Adult NondependentÂDrinkers. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 493-504.	1.5	23
38	Dynamic network dysfunction in cocaine dependence: Graph theoretical metrics and stop signal reaction time. Neurolmage: Clinical, 2018, 18, 793-801.	2.7	27
39	Resting state functional connectivity of the amygdala and problem drinking in non-dependent alcohol drinkers. Drug and Alcohol Dependence, 2018, 185, 173-180.	3.2	38
40	Problem Drinking, Alcohol Expectancy, and Thalamic Resting-State Functional Connectivity in Nondependent Adult Drinkers. Brain Connectivity, 2018, 8, 487-502.	1.7	22
41	Motor Preparation Disrupts Proactive Control in the Stop Signal Task. Frontiers in Human Neuroscience, 2018, 12, 151.	2.0	15
42	Thalamic Cortical Error–Related Responses in Adult Social Drinkers: Sex Differences and Problem Alcohol Use. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 868-877.	1.5	13
43	Resting State Functional Connectivity of the Lateral and Medial Hypothalamus in Cocaine Dependence: An Exploratory Study. Frontiers in Psychiatry, 2018, 9, 344.	2.6	36
44	Sex differences in the interacting roles of impulsivity and positive alcohol expectancy in problem drinking: A structural brain imaging study. NeuroImage: Clinical, 2017, 14, 750-759.	2.7	38
45	A neuroimaging study of emotion–cognition interaction in schizophrenia: the effect of ziprasidone treatment. Psychopharmacology, 2017, 234, 1045-1058.	3.1	5
46	Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Multiple Sclerosis and Related Disorders, 2016, 5, 53-65.	2.0	77
47	1,25-Dihydroxyvitamin D3 Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2015, 10, e0144084.	2.5	15
48	Psychopathology in Substance Use Disorder Patients with and without Substance-Induced Psychosis. Journal of Addiction, 2015, 2015, 1-7.	0.9	14
49	Depression in multiple sclerosis: A long-term longitudinal study. Multiple Sclerosis Journal, 2015, 21, 76-82.	3.0	66
50	Prolactin in combination with interferon-Î <sup>2</sup> reduces disease severity in an animal model of multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 55.	7.2	24
51	Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study. PLoS ONE, 2015, 10, e0123824.	2.5	25
52	Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Canadian Journal of Psychiatry, 2015, 60, S26-34.	1.9	42
53	Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair. CNS Neuroscience and Therapeutics, 2013, 19, 737-744.	3.9	44
54	Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. Community Mental Health Journal, 2013, 49, 317-322.	2.0	6

SIMON ZHORNITSKY

#	Article	IF	CITATIONS
55	Prolactin in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 15-23.	3.0	37
56	A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia. Frontiers in Pharmacology, 2013, 4, 100.	3.5	26
57	Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals, 2012, 5, 529-552.	3.8	155
58	Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophrenia Research and Treatment, 2012, 2012, 1-12.	1.5	67
59	Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders. Drug Safety, 2012, 35, 819-836.	3.2	28
60	Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Research, 2012, 200, 237-241.	3.3	40
61	Evidence that the reward attenuating effect of the D1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2c receptors. Behavioural Brain Research, 2011, 217, 467-471.	2.2	5
62	Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case–Control Trial with Quetiapine. Frontiers in Psychiatry, 2011, 2, 22.	2.6	12
63	Tolerability of quetiapine across psychiatric disorders. International Clinical Psychopharmacology, 2011, 26, e149.	1.7	0
64	Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders. International Clinical Psychopharmacology, 2011, 26, 183-192.	1.7	39
65	Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile. Clinical Therapeutics, 2011, 33, 1853-1867.	2.5	14
66	Relationship Between Insight into Cognition, Extrapyramidal Symptoms and Mental Illness in Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2011, 45, 596-597.	2.3	10
67	Antipsychotic Agents for the Treatment of Substance Use Disorders in Patients With and Without Comorbid Psychosis. Journal of Clinical Psychopharmacology, 2010, 30, 417-424.	1.4	34
68	Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders, 2010, 25, 2188-2194.	3.9	21
69	Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 997-1000.	4.8	14
70	Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine. European Neuropsychopharmacology, 2010, 20, 695-703.	0.7	7
71	Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opinion on Pharmacotherapy, 2010, 11, 2947-2951.	1.8	4